| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.41 | 3e-14 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 3e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.26 | 5e-06 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.21 | 0.0002 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.1 | 0.07 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.08 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.074 | 0.2 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.074 | 0.2 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.068 | 0.2 |